Blueprint Medicines (BPMC) 4 May 232023 Q1 Earnings call transcript

Company Profile

Participants

Jenna Cohen	Senior Director and Head, Investor Relations
Kate Haviland	Chief Executive Officer
Philina Lee	Chief Commercial Officer
Becker Hewes	Chief Medical Officer
Mike Landsittel	Chief Financial Officer
Fouad Namouni	President, Research & Development
Christina Rossi	Chief Operating Officer
Reni Benjamin	JMP Securities
Brad Canino	Stifel
Ernie Rodriguez	Cowen and Company
Dane Leone	Raymond James
Eun Yang	Jefferies
Matthew Biegler	Oppenheimer
Ami Fadia	Needham & Company
Andrew Berens	SVB Securities
David Lebowitz	Citi
Zhiqiang Shu	Berenberg Capital

Call transcript

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good morning. My name is Kelly. And I'll be your conference operator today. At this time I would like to welcome everyone to the Blueprint Medicines First Quarter 2023 Financial Results Conference Call. All lines have been placed on mute to prevent any background noise. there a remarks, session. speakers' the will Q&A be After [Operator Instructions].

begin. Jenna please Cohen,

Jenna Cohen

This a you Welcome topics and XXXX call. everyone. good we operating we Blueprint conference Thank today. morning, quarter plan to to and outlines release, press which Medicines discuss first results morning, the issued financial

as the at Investor slides section our as website that going we'll You can well by the access be to www.blueprintmedicines.com. press release, the reviewing today of

Chief Namouni, Lee Officer; Joining Landsittel, and Chief Research Officer prepared Executive joining call Operating Chief today Officer; Becker & are Chief remarks Haviland, Medical our Q&A. Philina with and Hewes, Kate Chief are Officer; Financial President Development; Commercial be and Mike will for also Rossi, Officer; Christy Fouad of available

to of those materially, to subject may uncertainties with I'd the that call cause you SEC. results the during our begin, and the differ our made number are we forward-looking including and some today actual that described filed of in risks Before like reports statements statements a are remind to

now to Kate. over hand the I'll call

Kate Haviland

the of What we at we good achieve and business execute we year year advance clinical scale. even everyone. launches, precision Last our growth XXXX as vision that what programs, ability bring our our to Thanks Jenna, scale innovative at a and strategy Blueprint, heart morning clinic. to the into is operations introduced call five lies compounds our on commercial more

to are years tremendous the the performance in value of Our progress poised that has first quarter deliver ahead. driving shown XXXX and are certainly we in

In quarter, well by the uptake moment, detail resulted favorable in Philina success net discuss in more our We QX. and strong execution drug. SM. continued achieved patients demand, product will driving a and as performance million as we First, advanced commercial in growth delivered dynamics of revenue commercial the AYVAKYT for by strong on in AYVAKYT that proportion in driven in $XX.X

to our continue advance we Second, pipeline.

after BLU-XXX to trial partial VELA within resolve the a hold resuming working of clinical expeditiously FDA with are We the weeks.

well FDA the face need. the of Our investigational agencies team's coordination working how fast collaborate we progress in and regulatory the with to which landscape, medicines with bring our emphasize, patients evolving to we an regulatory ever urgency with are and in

same our Third, distinguished for the three key call. We at programs. at and announce investigational data development inflection having expansion commercial AYVAKYT data a the at with share into towards the we best-in-class the of escalation ASCO, can by innovative our across same we advance a more next our time present pipeline product points breadth expect that later dose Becker -- launch Blueprint ASCO medicines. major at of label. opportunities our what we'll on is while heading across you of new are about will month

for a out now are We date PDUFA from and couple our indolent AYVAKYT SM. weeks

Our further field patients ready and in are leadership to pre-launch ASAP. support Blueprint's will teams approval solidify and in are the providers approval. activities This market upon on healthcare delivering

our team SM and bar a enabling will realization are confident accelerate $X.X therapy AYVAKYT to both as our the of the cornerstone opportunity. for market we first the As than the best-in-class what billion franchise of ISM, greater establishes be

we discuss it Philina? turn have progress to AYVAKYT me let Philina the and our our commercial to with Now over execution. confidence go-to-market in

Philina Lee

of strong the Thanks, quarter U.S. net $XX.X in morning including first generating a had We million AYVAKYT Kate. revenue $XX.X everyone. million, Good product

more the in AYVAKYT several over patients quarter XXX new of added business. patients revenue was sources at XX approximately of Let's and We on capture accounts driven by strength the grew our with XXX continue was commercially. to drug the the with to number we Half switches. increasing across to were the therapy new quarter more instead accounts growth starts on The this fundamentals due nearly look remaining as of free a receive U.S. patient greater the of prescribing in on AYVAKYT growth based AYVAKYT growth demand of of breadth able saw half in experience, some patients of we detail. key this in this exiting We than reduction to XX% AYVAKYT and percent and patients

We this the to free patients and benefit expect levels to QX. be temporary by of to the of return typical drug end on proportion more

activated training and end the the of team since completed the have who also our hiring expanded of and quarter. engaging We've field members customers been

With The are team in we advanced of the is place, growth us head the for into to continued to our strong ISM highly start launch. experienced force we off great full giving ISM. year ready drive and momentum SM in we a expect as

We been deliver many unlock the ready with more for opportunity living patients have never to so SM. and

look to Let's next. that

just ISM is Blueprint Medicines from the are XX We days PDUFA electric. date our in at energy and

is team are is Our ready, and the AYVAKYT. market ready, waiting for patients

patient of and activation, launch provider healthcare pillars our shared engagement, have the We strategy, three access. previously patient

consolidated each have We of three areas. launch ISM across these our preparations

of unaided First, immunologists, industry have Among approximately from benchmarks. allergist and double engagement. grown we provider would to XX% patients awareness expect AYVAKYT ISM, with or Hem/Oncs managing what you

most teams to field built likely healthcare to relationships with volume and have XXXs high providers identify patients profiled need who initiate in Our of are AYVAKYT.

that on people leading to post-approval. campaign mg fill. patient dosage channel And information will approval. frame strength who And These the continues secure upon strategic receive coverage. the XX frame broad SM payer already is focus disease progress It's something performance also to drawing Blueprint launch with access, awareness program to in signed about XXXXs pillars three our industry times more the metrics support our are AYVAKYT and up your to activation. patient of third Second, is unbranded our

and drive as provider patients in to allergist an maintain the And patient looking for access is patients In progress, important will and therapy label through coverage AYVAKYT immunologists breadths, like ISM, engagement to AYVAKYT. as relative prescriber activation, lead of We'll ISM track a be particularly goal to measure growth. at disease in patient on well is to revenue indicator a with strong to look chronic we'll our the treat decision number payer For continued growth launch. our to therapy. in of in also growth

As our the our I story a with SM story. team last is at meeting month, national Blueprint shared field

We are for we're ready to opportunity and there The is deliver pioneers. the patients.

have right the medicine, the We right we and to team, launch. ready are

with it for will our to across over as we I'll And that, hand progress prepare Becker, share burgeoning who ASCO. portfolio

Becker Hewes

first-in-class clinic, in Blueprint cornerstones morning multiple Blueprint become profiles treatment. are compounds the and We of good an of operate and preclinical EGFR everyone. therapies of that on Philina, could other best-in-class exciting key if future Thanks, and premise our Medicines pipeline CDKX targeting the potential has the born out targets.

will We an Phase last we continue presentations update as announced the of programs. towards dose escalation X week towards recommended acceptance on that to progress our X, make data ASCO defining doses three goal. that of at work And across provide we

as ribociclib. modulation. for will our inhibitor data and First, monotherapy, combination data will BLU-XXX, selective clinical safety as safety, be evidence is demonstrate maximum inhibitors we other like of agents The on other the breast pathway we vulnerable our of cancers. focused at initial profile in advancing anticipate The treatment such have CDKX/X and benefit particularly with here of ASCO that CDKX BLU-XXX CDKX important cancer

in parallel in monotherapy of continue breast ASCO, patients. escalation we dose in cohorts of will cancer the and Following enrollment ribociclib continued combination

BLU-XXX These cell clinical we in EGFR Second, clinical activity, initial data cancer. early lung mutant that will and evidence show for exon disclosure our activity for XX of non-small reinforced best-in-class data including potential CNS have safety BLU-XXX.

at regimen ASCO and cohorts work dose to dose We're optimize will escalation continuing to progress and a through to date. show

of combination with and tolerability monotherapy be EGFR EGFR osimertinib Third, of additive dose both osimertinib. combination EGFR in mutant the the safety combinations failure we osimertinib heavily to escalation is remarkable previous presentation other will targeted This A given will present EGFR on as a wild-type and updated due population. key in toxicity. focus BLU-XXX, inhibitors with patient of in data pretreated tolerability with and BLU-XXX this

to as reach towards milestones we track are updates. month make urticaria I'll Blueprint. nomination We progress other the next a financial on pipeline over targeting milestones We wild-type these look XXXX forward development of to our this With candidate data more important call and Mike for our of kit sharing well, as middle that, turn chronic the to our year. in for including review

Mike Landsittel

this the from quarter. in from detailed and financial release reported today's $XX.X press license in few revenues Thanks AYVAKYT and collaboration quarter, product $XX.X the a in revenues million we've for and Becker. our first highlights results on In revenues. total million morning, call, sales of million, Earlier net I'll including $XX.X touch were

As Philina noted, one-time expect saw revenue quarter-on-quarter we in growth goods helped that as that drive AYVAKYT favorability QX. to continued in as growth well unwind free demand we

XXXX for that in year pleased quarter. our and mix revenue our updating with to patient guidance product first are this We we AYVAKYT are reflect early net favorability now the observed the progress

of now and SM to on quarter our approximately for $XXX advanced GIST. to million is full indications million prior our date, Based of anticipate anticipated last our QX We $XXX revenue launch. ISM PDUFA currently our approved

early ISM do we As including launch as noted, be guidance so. not it plan this to the year do issue in will have we too to

to expect this We patient through SM continued see year growth driven by in demand. Advanced

will growth ISM of driver in year. main the into AYVAKYT be second of expansion the label anticipated the Our half

for we we the were Financial out the to costs saw a showed priority expenses discipline expenses, quarter. total for our remains now third consecutive million operating play and quarter. expenses first Blueprint quarter-over-quarter operating Turning as declined and $XXX.X for that

Similar be expect launch year of and we clinical to then expenses flat related our half expense OpEx the last relatively pipeline of quarter, for operating in first expect a to preparations and year. the the in remainder increase from guidance quarter-on-quarter the slight a investments to

of OpEx In this commercialization related we GAVRETO related in do are and anticipate from transition. February, for we not the any We Roche. to process that XXXX incremental development in rights announced impact regaining

drive forward we initiated believe GAVRETO have to as on going a is re-partner we model our focus to that value prioritize We the process SM. best this as

as been financial that in position unique strong de-risked a across grow significantly medicine clinical $X clean disciplined progress a reduction cash as exceptionally will commercial to generate burn, has with Blueprint a cash annual revenue that position planned expect in continue we and continue in around are remain and pipeline. expenses. operating we nearly revenues our make an has story a and operating AYVAKYT breakthrough We Medicines on and a in that billion growth is remain trend and our assets we multiple We

over financial achieve and for for strength This turn the shareholders. call our I'll XXXX transformative create questions. fuel that, precision now will operator With continued and to at Blueprint scale the value Operator? to patients help

Operator

Thank Instructions]. you. Thank you. [Operator

Jefferies. Your from go first Eun Yang ahead. question Please of comes

Eun Yang

you. Thank

kind types advanced based and of uptick anomaly you advanced on in So in is what think that terms expect? our do you SM, quarter of a about you talk drove of SM why AYVAKYT could what might quarter-over-quarter, increased seasonality kind actually you last patients of in really, third population year saw

Kate Haviland

thank So Eun. you,

terms able So of QX what I talk see is, of the million was a about see $XXX in growth SM see is that to very the what what what the Philina we're SM want the patients asking $XXX you're part we before to of we're do mix think advanced you believe what guidance base to dynamic in kind the your in you're quarter-over-quarter And SM question, to growth? to of that's then and the lumpiness is just happy going year mix disease is and we've of important to and to kind be mentioned but raise course to I million, the I be here a of advanced quarter-over-quarter. think lost It's first the that, we there. going advanced asking really dynamics much happen over our but rare and

Philina Lee

Eun. thanks Yes,

the market I'd coming extremely SM-AHN. your into share really we of the the SM to about across encouraged growth with QX were of subtype quarter-over-quarter starting patients in mix, where the AYVAKYT common out pleased we patients see question growth say again many who SM-AHN, to of growth, of in XX% most XX% which with QX. So subset were in a subtypes have To we advanced growth especially is saw see

our something significant about, pace in measured launch talked be a to of pending AYVAKYT the launch. advanced at approval, our ISM in forward. expect we've going growth SM growth driver that more albeit see, greatest But with we early stages growth is source is As continue which to ahead of most the we than

Eun Yang

what for the to so to ISM, want you mentioned know FDA were past A in follow-up make comment FDA, a get the you. the action you label if still label Thank ISM? a from broader expecting close that expecting but that don't you are to so date, as I broader is we you

Kate Haviland

So hey Eun, this is Kate.

really this So we good and agencies. the as think we're the said, what a ISM PDUFA. we for on having track, don't close talked regulatory discussions we've action on with about are I a really to date, you our the and having we're on from perspective about the don't of collaborative expect discussion label we're track kind talk Things

Eun Yang

you. Thank

Kate Haviland

Thank you.

Operator

Thank you. you. [Operator Instructions]. Thank

Richter Our Salveen ahead. next question go of from Please Goldman comes Sachs.

Unidentified Analyst

[Indiscernible] Thank for you for question. Salveen. our taking

any one on planning and the patients? you're mix the raise controlled have switching for care? you. the Just place assumptions with have supportive could that other best that target the just adequately underlying that's to on in Are how guidance. driving quickly Do there of the physicians us ISM you just the walk through a patient then those you are patients Thank launch, outside mechanism

Kate Haviland

question. the for you thank So

there your I a the increase composition free mentioned business, we in in other dynamics. a in which her base shift. One is first Just of different the part the XX% goods, temporary a goods, prepared was two really And the in a talking is was about mean, Philina patients change the growth the on -- of shift which number question, was free remarks. that which mix? is the saw the of

The who get to a just a job find the to paid way QX patients into for the great therapy goods traditionally free team on been did for quarter. in would've

very innovative And do was, Philina, no in mix the was our so very in patient and and quarter. seen change about that in growth provided certainly tailwinds there line that the a able talk was guidance. you to about we how ISM? was in we it's we've with thought line But saw thing previous team with really want before do what to our much and

Philina Lee

heard that from sort we I treatment and activate think how are what treat of need providers urgency directed I to move second patients around in with question who so targeting is polypharmacy AYVAKYT. are Yes, have your really and doing to symptom to alone we

a really are as AIs treating couple about care actively key volume strategy And X,XXX is XXX, times diagnosed health to top and highest so focus their today who moderate engaging severe provider system, patients, a target talked are the of with ISM our the a Hem/Oncs on the year. to seeing approximately of we've already average

created to that, addition is armamentarium right? we of a In have territory equal. substantial not tools, So every

top capabilities them. extremely have to are patient for volume ABMs them so equipped of most to those are centers about their be are able with there as in And are their engaging relationships see where severe talked high who on we've And ISM journeys those and that terms local our that targeting now customers. also leveraging providers. They powerful of intel data patients with

that's with of secondly that them I and of becomes really caregivers the new how sort part of to that kind a a front. to And them, think drive literature to actually as of let your substantial that second I question, combination know The was with I think might reframe switching, providers And of option treatment engaging activating again, when around and there's conveying for really treat urgency activate the available. and disease burden on with patients AYVAKYT.

Unidentified Analyst

you. Thank

Operator

you. Thank

question go come next of Securities. Please from Our ahead. Benjamin JMP Reni

Reni Benjamin

mean, follow-up, about? you kind progressing? what's as talk you you to Thank You get Can here? that give you. And engagement top you this can the to Is And awareness payer an just of be XX%. even guess about or XX% discussions to the of little as of that quantify plateauing us XXX? we is maybe bit ultimately the how launch, think update as stats to a grown should you this growing just I talked XX% that unaided just that provider denominator are closer to thinking go mentioned? a can XX%, something do is higher I

Kate Haviland

question, Thanks for Reni. that

innovative and We possibly of want do are But the the you are to is that? medicine as this them. and with details out data Quad of how pleased really talk aware where to mentioned today AI, Philina of that on of some physicians the sit we both just Philina about receptivity coming coming about

Philina Lee

of question around awareness first the Yes, so your was think the metrics. I part

So again, And Hem/Oncs the at encouraged just we're I who among today. unaided are allergist to immunologists, see think that's really XX%. treating ISM actively really the awareness patients and

beyond at So saw in this the that, we And providers, out AYVAKYT strong top awareness Quad coming above this XXX of and AI, the bump to especially including allergist XX% well immunologists. a addition awareness the aided among is point. in of

further towards it's do the get tail plateauing. refers. and say, not as volume of we work certainly There's into to of out of treaters would sort sort I lower and So

getting of part in maybe think of are of upon question pairs your expectations was second terms access our access launch. sort I with at what The and

So payer sort and of are seeing see, on performance And patient including code Post reimbursement. insights doses our as There's approval strong we the the of we've maintaining will said, SM the as five we based strong anticipate are what and XX one certainly AYVAKYT milligram. market, for of we really be focused on on well. current access. all

for scripts seeing are we well. are seeing we So good getting of small coverage those with proportion that ISM the today, as

Operator

Thank you.

next go Canino of question Please from Stifel. comes Our Brad ahead.

Brad Canino

less thoughts, I may on that to Thank much year, Hear be world question. so quarter. your treatment in physicians on XX% a I may meeting the up trial you. I AI. shape particularly for around get if a real risk received the after at real durations? XX% reduction than of world? questions the and shorter that symptom for patients in with want cohort ask thoughts on ISM Thanks since launch, Congrats how Quad Great. ISM after really the the guess durations the the around preliminary

Kate Haviland

question. on can Brad, that? weigh thanks in So Becker, for you And your

Becker Hewes

Patients is on to their TSS that symptom. that it's remember derive measure. most a score binary think benefit I bothersome Yes, not it's important Brad,

that going total -- the they TSS Sometimes includes down. score

it of on what's time from Sometimes that have on part for one after including benefit. the derive remained remain the drug But long the the at patients TSS all doesn't. really patients that important many on in patients that most levels the And very that is a study for study years.

I don't beyond of going that benefits treatment, to then So learn to patients is many we're going in measured score. be And for going patients. lifelong TSS by to we're to think be. believe the what is that yet ways say continue This the a what's I to all position AYVAKYT duration the

Kate Haviland

on It's as broadly AI rate just is certainly see the this mean, by about in the I patients of three there and we AYVA you something which a And think we have XX% before, are roll that I gone and certainly to two add, we've they that criteria relevant metric would as into continue when part said benefit. put data part Brad, strong patient who think about out on the over really this with, mentioned hematologist I of of really with are discuss also familiar a not context response vote and protocol. oncologists that having therapy with AI we've is the trial part data, that's to testament community. a their that in clinical place with the rate feet. a really that really mean, can that We've think we don't response I be patients them, but with in

Operator

Thank you.

Our of Marc next comes go TD question from Please ahead. Cowen. Frahm

Ernie Rodriguez

the the and a have Thank the on a Good AYVAKYT my quarter. guidance. follow-up bit Congratulations We for Ernie Mark. questions. taking Rodriguez on for couple morning. you just This on is --

drug exactly was drove, that think So why some And be drove a if of use about you it approval so you we're I temporary? also on the think from getting free any and what So in FDA close it expected do drug. that percentage of the reduction you the what going should then given And we of patients forward? would the growth saw to off-label in ISM. wondering mentioned wondering came how

the address guidance. And is determined guidance how expanded? you. then Have you Thank plan question on guys label once a second you AYVAKYT to

Kate Haviland

going appreciate questions. questions those We're to the and lot try to a for given just this everyone Thanks that has keep of queue.

on and growth. we how two answer last helpful way quickly, thought I'll can maybe the no questions So about Ernie, get in we your on,

do the so on ever first any It's a days going therapy launch, approved in no, issuing this not in be So disease approval. we guidance additional we state, anticipate be the guidance. will providing upon ISM not to early

And same it then at as that usage was little so we've last the off-label had all, very quarter. that remains

but have patients, not a few many. We

weigh can the about kind on thought Philina, the maybe free with So you and of we've patients? happened in what growth how goods

Philina Lee

is of we quarter instead this free the to saw that due goods. commercial we shift patients a was proportion saw what a greater receiving growth so to of therapy of half Yes, that

is And benefits QX their where so what and re-verify in status. that patients process happens through go a their they

re-verifying and have a support status. help your very We their of program, process patient Blueprint, patient robust normal it's that part in to

In unwinds onto sources reason, therapy. so to patients as one-time qualify of to over that able this they're such and then resources second And available a move foundations. cases, that free course go they're drug finite, financial here some may for benefit third-party be able and onto if charitable the commercial we assistance quarter. of additional to for are this off The temporary of expect

Becker Hewes

anticipating AIs the about and the So I in to like with also talked most it's typically waiting trend is comment that are that label, Hemo. add it that note general not ones a for but they anxiously and don't one we've off-label of prescribe just important that's

Ernie Rodriguez

Thanks. helpful. That's

Operator

Thank you.

Our question of Dane ahead. come next from Please Raymond go James. Leone

Dane Leone

thanks. for finally getting Hi, me Thanks connected here.

just two me. So for

there. the actually made that that was last clarifying point Just

of trying more to this are well. things second going are going ASM? So cadence just coming understand frame we month. people first to think the confident Obviously to out the quarter What it approval broadly, expect raise that obviously going should where the into you your I feel you guidance. you're quarter get with

to momentum on on that there's shift the drug. patients going pre up back be some commentary ASM in picking You're to

later for for moving to XXX So frame could maybe all of the for ASCO, us efficacy those population pieces. quarter And the anything help at to then little that your that on between so just we're there all just it for like be data more with that plus could you the a expectations us be frame see kind to well. will seems dialed osimertinib first quickly curtain look the we action? into maybe second should you razor Q-on-Q just see ASM Can expect get based some bit, initial combination in helpful we But to a we'll would expect it of obviously mechanism signs as year. the Thank LXXXR patient maybe of you. what

Kate Haviland

Sure.

So the to about Mike, first that point Dane then expectations ASCO. you QX take making was maybe for Becker can we'll over just for hand around business. think how And to you core the it

Mike Landsittel

Yes.

to not yes, in as to saw Dane, in business expect so QX due goods mentioned. So impact the at we And rate our free what see by it AYVAKYT that's so guidance almost this we could and the demand, we've it's that in we the think of Philina run the quarter-over-quarter approximately you as growth same be growth that mentioned, of in-patient but million, reversal about free to impact continued goods was. $X our increased going -- we

in so can consistent see Philina guidance. increase our of about that off growth what almost you we And forward said. moderate with still consistent as of closer being to revenue QX the million. grow expect is to going that to for base think off And $XX And with like

QX I other think approval. to yes, we are ISM for be going getting important the is anticipated point

pretty back year. in really be the to the for to see This the you're Where of half going is quarter come ISM minimal. impact expect growth the ISM we

Kate Haviland

And ASCO? Becker, take you Yes. XXX for to want the question

Becker Hewes

Yes.

we're our So That plus about. combination. part thanks the very the is for combination of mentioning study. Phase Dane X OSI excited a update that This on is XXX an

complex are looking X combination. is time really different tumors. this two in pretreated of patients combined. know, you This tolerability of safety at that inhibitors that here have the profiles doses full we're side really and As being EGFR effect with quite heavily are What Phase and first is

in past. the We shared data validate that we've some the the the they're look and of that hit expected to data mutations compounds to, that activity to

And that's a the efficacy what the focusing at respect population. so with in are patient expectation heavily really is ASCO. to appreciated safety we on But

Dane Leone

Thank Great. Congrats. guys. you

Operator

you. Thank

question of ahead. Our Guggenheim. next from go Please Schmidt comes Michael

Unidentified Analyst

question. Hey, this one ASCO. at data for is the Paul taking on have I Thanks Michael. on for BLU-XXX

you one for potencies And next a Just squeeze line practice that quick then confidence in initiated you a is how those helpful. to wondering Thank the if exon maybe the if anything in can That'd super of setting? you targeted on re-partner how of gen shift some about are to on a in you. I the sort second thinking set therapy GAVRETO, partner expectations, could plus bar XX in could near-term? finding share you've be sort your and new treatment

Kate Haviland

Yes, so GAVRETO maybe XXX, take question. the address for thank but the Becker you can I'll just first.

impact an lot GAVRETO on of will cancers, a with RET-driven we've a that a are important a and that has to we perspective, is we from got for very interest. tremendous be confident So patients it able find great partner this medicine And product.

to highly you that to then we're going a find do so go maybe want great Becker, we're confident And And BLU-XXX? to partner for able that. be to

Becker Hewes

EGFR. blood-brain ability acquired exon everyone, cross hitting and is the hit Yes, so just its barrier we wild-type without a to to XX BLU-XXX compound to remind for

So the toxicity other of nervous with And patients compounds. we've be seen is common most to for the a which spare some of able system. relapse, then what area the to to central address

So escalation now, we're right escalating. still in dose

we've expect an dose all that early activity levels. seen. don't from showing are We've study, is that seen the already of -- what anticipating not shared at ORR I'm we this of the we've level activity So but

an this nervous will activity be as we central So and on escalate this system compound. update continue the to

Unidentified Analyst

Thank it. Got you.

Operator

Thank you.

of go ahead. Baird. Beatty Joel from Please comes question next Our

Unidentified Analyst

had driving expect question. a SM-AHN? Benjamin just our Joel. is would this [indiscernible] Thank on then I the for And Hello, in to that question. XX% continue? for taking growth Thanks you. What's clarifying you

Kate Haviland

we've doing you work Sure. about want been there? do talk the SM-AHN Philina, and to the

Philina Lee

Yes, that thanks question. for

we encouraged really mentioned, as the in growth market to were SM-AHN. share So see you XX% into

that on just have and and their education and small think patients there attuned proportion there to providers the treated the market, I most SM the who awareness more of where of still advanced for context is are the of patients a SM overall treat focused the SM being the the for these it's SM into Hem/Oncs relatively have is to urgency AHN. SM-AHN been the treating really the traditionally dynamic

space treated to patients a it of there's still a lot the primarily their of SM. question, just order think answer overall of on who being head are minority is I your because like for still

Operator

Thank you.

question next Biegler Oppenheimer. Please from of go come Our Matt ahead.

Matthew Biegler

Thanks for the morning. good question. Hey,

positive modeling to you to don't out sales yet, code that guess you So concrete relative And PDUFA, ISM separate concrete the guidance? ASM and able get a guidance Thanks. be but give AYVAKYT I provide to to you forward, ISM for assuming going is want break I think J as we do sales? sales about and expect needed to appreciate will

Kate Haviland

So for question. the thanks

talked what code before we've is SM for actually is that the same. the So about

do breaking will not the just We So versus flows. certain we insight into that have product full which certainly be level dynamic, out through we channels have of not ISM a but SM. on advanced the visibility based

the to the breadth started to talked sure the around using new which looking last activation And We quarter, that's accounts. prescribers impact all here launch you new help putting and patient think starts, launch. going be the how include about the we've at and some making KPIs be updated we'll we've of of out will of and about we of

as Philina, do to people are look ISM those the about metrics we the health launch. of towards that? want types you the add to we'd suggest of think So that

Philina Lee

jump what clarify said. completely agree with Kate and Yes, in just to

report new one with patient but clarify, is to going the that AYVAKYT point the not starts, on total Just patients the we therapy will it's forward.

Matthew Biegler

right, thanks. All

Operator

you. Thank

Ami ahead. of from come questions next Fadia Needham. Please go Our

Ami Fadia

of you talk the some us Hi, about if physicians taking already you question. quickly ISM do under patients? at my color how for qualitatively, to AYVAKYT maybe good their some identified are many that can Thank them prescribing and on AYVAKYT give morning. care that patients Can ISM see least you've are prescribing and you. you Thanks how their

Kate Haviland

Ami. Thanks,

to current we we you do to adopters of of early you're think weigh I experience, be So in one on kind be Who launch? have Philina, do will do that some dynamics those are about that? in about asking groups? what and those want physicians the early the think is expect who how

Philina Lee

we've part first into the good around question estimate the breadth for foundation moderate a accounts, XXX the managing is around talked to base the XXX so patients. of so prescribing current current your ISM We which diagnosed great launch. AYVAKYT, ISM for severe about, indications, there's that prescriber of to Yes, heading as already really is

going of question are of immunologists is predict, alluded particularly Kate existing they a to a have we a those new well that of therapy, the to second trajectory prescribers early important going first in the it's from hard our belt. The really to really KPIs reception quarters be launch. And those tracking under predict of both why again, of these excited exact our engaging I around market allergist AYVAKYT prescribers, ramp. was early And we as to to cadence to early as and as and have are that's be in expect the approval. the your so number that think that ramp and So couple received right? we come to new truly quarters are waiting part so harder a And until always for are speed really

Ami Fadia

there. And maybe quick follow-up a

XXX these ASM AYVAKYT Are out them of they of presumably of are predominantly? because sort are So oncologists accounts, mostly all patients? to prescribing they

Kate Haviland

Yes.

Ami Fadia

Got it.

you. Thank Okay.

Kate Haviland

yes, your oncology. the indications are current primarily to managed So is the question because by answer

Operator

you. Thank

Our Please next Andrew of SVB question Securities. comes from go ahead. Berens

Andrew Berens

without integrating impact me. if program what Mike, in potential but Hi, and first Maybe you're integrate GAVRETO cash the divestiture the trials have program, assume is expenses CDKX XXXX a runway maybe it, re-partner one thanks. add and Does XXXX the ongoing trial partner? question to impact I to on your hold the what the to of trying program is a said the removed? wouldn't Two questions for you to then have the clinical have manage for the you protocol the GAVRETO you know in and did to

Kate Haviland

Becker, how on about we're go do any starting want thinking weigh we our So Mike, expenditure then discipline and with additional XXX. GAVRETO, And maybe you around in to view just on that? our can to

Mike Landsittel

think see feel about that to future beyond any forward. expense, see like we And belief operating Andy that years re-partner I planned. our benefit how leads not year in will we Yes, now, possibly going If we're is to so what incremental in operating or this a very GAVRETO we expense that process impact could going. we we've the yes, as confident mentioned, anything,

very We that don't we any So anticipate about position. confident guide to feel our impact we how on long-term sustainability.

Kate Haviland

to we we I'll expenses know lot about operating way, not be that our and assumption, have in an want going And our Andy, lot your I what and do amounts is to choose you a of we that talk over to capital on, about any think do that is have significant rising that. form or of this we shape that you allocate Yes, that forward. Becker, BLU-XXX? just we're of money again, to models to do a add in to nor spend as intend area going our control

Becker Hewes

the and hold reason was delayed the data. because concern of listed part the Andy, went the quickly is through minimal so was changes the we Yes, were when

then baseline ophthalmologic But was criteria the patients, and and toxicity protocol. exams the follow-up. for that had So they'll only added that FDA to if we patients a real additions get the were symptoms,

Kate Haviland

anticipate don't like that? of anything enrollment will anything or you change that cadence the around And

Becker Hewes

expected and for No, no there's change patient.

Operator

you. Thank

question next from of Citi. go Lebowitz David Please Our ahead. comes

David Lebowitz

much very Thank question. taking you my for

one-time AYVAKYT, Regarding the the benefit? charge increases for not the quarter one-time the assume we in guidance the that the charge, from incremental one-time change can in primarily or

Kate Haviland

Yes. right. exactly That's David. Yes,

David Lebowitz

Got it, got it.

Kate Haviland

That's exactly right.

everything So be expect that's the we same. to else

David Lebowitz

when you're terms ISM takes therapy should like get the of in to, not but from that, and we you ASM Got between on or you differences understand the given when ISM to able it give look what prescription launch, how be to potential forward on a I it. attuned any such going anything guidance population not look dynamics being cadence, for, And launch, the to and long patient to forward, items? you're the other

Kate Haviland

already the little that, call to mentioned ramp cadence that think a about has or reiterate and want today to how the about there Philina So bit talked that? on KPIs, Philina you do

Philina Lee

really most I the really polypharmacy, are difference there, and off think for would number that with been right? To area about with, start XX actively directed patients your of driving they're seeking think I biggest fold greater I have population So we're highly are treatment question urgency who Yes, really, mean symptom ISM. the on is and I is prevalent starting I starting diagnosed already around actually, to focused around cadence, patient treat the right.

still treated taking their of a daily to activities disease or in it living, on participate being While are and significant ability move agent. and symptom activities, is work switch limitations patients are need a to with these family patients for from therapy have behavior facing their to polypharmacy modifying still directed these

engaging the educating so patient really providers one core year. on the these disease areas cadence and work, both are of the activating and focus burden on that talked visits a patients. average times And of of is our them two We've about about

And so with important decision to treat this visits. to AYVAKYT urgency the really to at these education is the maximize and treat

Operator

you. Thank

next Lawson Peter of comes from Our ahead. Please go question Barclays.

Unidentified Analyst

taking Thanks Peter. for on our for [indiscernible] much so is question. this Hi,

and in little the growth ASM. the could there drug what trajectory really how dynamics maybe driven organic you market ASM there bump for add me, growth thinking excuse for like the by in sounds dynamics color for revenue, we much on of was ASM with rest free about year? two growth both it the in is Could also be the here So some a more and key for product

Kate Haviland

sure. Yes,

goods we due had advanced around was XX% about was for the base so Thanks SM the a and business to due what About said to quarter-over-quarter question. the growth that's in half free growth. that, favorability is, the the mix. we half So

Operator

you. Thank

Our come Please question Shu from ahead. Berenberg. Zhiqiang next of go

Zhiqiang Shu

for Good questions. morning. the taking Thanks

dose you the channel. you you to XX the the that to? use pathway modulation and second at program. the you ask already signal for were question in that terms about and want of to is can metric And ISM readiness talk significance launch you talk in around I made we going of one that, around about for mg very as the around also wonder well ASCO if of the as CDKX, I comment are is First analyst internally Maybe strengths population. can Kate, the referring in of earlier both much. BLU-XXX to metrics the patient see track prescribing the safety the Thanks importance then

Kate Haviland

color all one this know add us Starting They're gives I for fast a question, thing if you really Thank opportunity questions. in more that of can think by is the that is the and launch I I with unique really out-of-the-gate the fact that's strengths being opportunity mean, AYVAKYT to dosage are already and covered kind and don't you channel. that? and this Philina, mg any XX available those payers very about

Philina Lee

access we've I mean, I already. Yes, think to spoken part the

or doesn't novo needed are kind think label in. if in launch I channel. a exist market difference lag getting that the the a we it a coming time additional into of wasn't upon And were dosage and that right between would the this the for be that that there product situation yet and that de first strength launch is, time on the

Kate Haviland

that's have launch. this into we a great that strength So coming

you talk and little do BLU-XXX from what perspective? want you bit are what looking from a do Becker, you to a then a and safety So, expect about for like safety

Becker Hewes

selected get you CDKX just be was CDKX. hits to and a it hit hematologic does gastrointestinal so such not but designed can and Yes, when selective, BLU-XXX And toxicity. you CDKX, that reminder, highly hit

So various we this say have be going we inhibitor was doses active to What with is CDKX to is range. that ensure show that your really showing expect and circulating about an look effects without to wide we're pretty in type bonafide that people both that biomarkers a ribociclib. modulation the has at biomarker and and I'll of tumor-based a as And then second that front. we of that active range in think agent what when question seeing side both a about single important to combination

Operator

There are back over at questions the turn Haviland, no you. Thank call I'll further to Ms. you. this point.

Kate Haviland

to all continued thank remiss saying I'd we operator month taking be soon. be Blueprint it's there. not the going today and Wars of an Thanks given to to for the that for Xth, be you support look And out call with end join your you talking the time May exciting and for Force us to Medicines. May us the to and Star really all you forward It of all by fans is again for

all you to talking a weeks. to forward in look couple hopefully of again, So

Operator

This you. Thank concludes conference today's call.

now disconnect. may You

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.